Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance Glycomine’s substrate replacement therapy for PMM2-CDG (CDG-1a), the most prevalent form in the spectrum of congenital diseases of glycosylation (CDG), into early stage clinical studies.
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
Categories
Follow Us
Tags
AI
Alzheimer
antibodies
Azitra
Bioeq
Biosimilar
Cancer
cardiovascular
cell therapy
CE Mark
clinical trial
Diagnostics
Digital Health
Distribution
Drug Discovery
Enterome
EpiVax'
FDA
FDA approval
funding
fundraising
HIV
Immunogenicity
Immunotherapies
Licensing
M&A
medical device
microbiome
Neuro
next-gen sequencing
PathAI
pathology
Pepticom
pharma
RNA
robots
Shape Therapeutics
skin
software
SurgiMab
Therapeutics
therapies
USA
VIrology
Virus